Description: Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Home Page: www.connectbiopharm.com
CNTB Technical Analysis
East R&D Building
Taicang,
215400
China
Phone:
86 512 5357 7866
Officers
| Name | Title |
|---|---|
| Dr. Wubin Pan M.B.A., Ph.D. | Co-Founder, Pres & Chairman of Directors |
| Dr. Zheng Wei Ph.D. | Co-Founder, CEO & Director |
| Mr. Steven Chan | Chief Financial Officer |
| Mr. Jiang Bian J.D. | Gen. Counsel & Chief Compliance Officer |
| Dr. Lei Sun Ph.D. | VP of Biologics & Head of CMC |
| Dr. Raul Collazo Ph.D. | VP & Global Head of Medical Affairs |
| Dr. Malinda V. Longphre Ph.D. | Head of US Clinical Operations |
| Dr. Chin Lee M.D., M.P.H. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1939 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-03-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 108 |